News Vanda ends 40-year hiatus for new motion sickness drugs The FDA has delivered some end-of-year cheer to Vanda Pharma after approving Nereus, its drug for the prevention of motion sickness.
News Daiichi Sankyo denies AstraZeneca takeover report Japanese pharma also hands back rights to painkiller to US biotech.
Oncology Astellas’ banner year and focused R&D strategy, with Adam Pe... At JPM2026, Astellas' chief strategy officer Adam Pearson walked pharmaphorum through the company’s four-pillared R&D strategy.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.